Relevant studies have also elaborated and summarized the role of SENP1-mediated protein SUMOylation in the pancreatic immune response, β-cell damage, and the progression of DM, while also proposing the use of NEMO inhibitory peptides or NF-κB inhibitors as potential therapeutic strategies for T1DM (102). This evidence concerns the gene NFKB1 and diabetes mellitus.